Table 3.
Pro-SP-B and pro-SP-C in children with no SP-B
| pro-SP-B | pro-SP-C | |||||
| Detecting antibody | CTERMB | NFLANK | NPROSP-C-C2 | |||
| Mr of band (kDa) | 34–36 | 25–26 | 19–21 | 25–26 | ||
| Subject | Genetic analysis of SFTPB | |||||
| no SP-B 01 | no SFTPB mutation; marker exclusion | - | ++ | - | - | - |
| no SP-B 02 | 496delG homozygote | + | + | + | - | - |
| no SP-B 03 | 121ins2 homozygote | - | + | - | - | 6 and 7.9 kDa |
| no SP-B 04 | no SFTPB mutation | - | ++ | - | - | - |
| no SP-B 05 | 457delC/121ins2 compound heterozygotes | - | - | - | - | - |
| no SP-B 06 | 121ins2 homozygote | - | - | - | + | 6.6. and 9 kDa |
Bands reacting with the anti-pro-SP-B-antibodies CTERMB, NFLANK, CFLANK and NFPROX displaced by the CTERMB, NFLANK, CFLANK or NFPROX peptides are indicated by "+", or the anti-pro-SP-C-antibody NPRO-SP-C-C2 and displaced by the respective peptide are indicated by the molecular weight directly.